

# Dong Guo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/546813/publications.pdf>

Version: 2024-02-01

53  
papers

1,804  
citations

279798

23  
h-index

276875

41  
g-index

54  
all docs

54  
docs citations

54  
times ranked

2132  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long Residence Time at the Vasopressin V <sub>2</sub> Receptor Translates into Superior Inhibitory Effects in <i>Ex Vivo</i> and <i>In Vivo</i> Models of Autosomal Dominant Polycystic Kidney Disease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 7717-7728.	6.4	11
2	mPGES-2 blockade antagonizes $\beta$ -cell senescence to ameliorate diabetes by acting on NR4A1. <i>Nature Metabolism</i> , 2022, 4, 269-283.	11.9	16
3	Benzodiazepine Derivatives as Potent Vasopressin V <sub>2</sub> Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9295-9311.	6.4	12
4	Defluorinative Alkylation of Trifluoromethylbenzimidazoles Enabled by Spin-Center Shift: A Synergistic Photocatalysis/Thiol Catalysis Process with CO <sub>2</sub> . <i>Organic Letters</i> , 2022, 24, 4075-4080.	4.6	43
5	Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 85.e1-85.e11.	1.3	24
6	Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 221-232.	3.8	23
7	Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. <i>Pharmacotherapy</i> , 2021, 41, 205-211.	2.6	8
8	Pyruvium Treatment Confers Hepatic Metabolic Benefits via $\beta$ -Catenin Downregulation and AMPK Activation. <i>Pharmaceutics</i> , 2021, 13, 330.	4.5	5
9	Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3531-3541.	2.4	15
10	Divergent Regulation of OCT and MATE Drug Transporters by Cadmium Exposure. <i>Pharmaceutics</i> , 2021, 13, 537.	4.5	4
11	Lrp6 Genotype affects Individual Susceptibility to Nonalcoholic Fatty Liver Disease and Silibinin Therapeutic Response via Wnt/ $\beta$ -catenin-Cyp2e1 Signaling. <i>International Journal of Biological Sciences</i> , 2021, 17, 3936-3953.	6.4	2
12	Moxifloxacin derivatives with potential antibacterial activity against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, .	2.1	1
13	Cadmium exposure enhances organic cation transporter 2 trafficking to the kidney membrane and exacerbates cisplatin nephrotoxicity. <i>Kidney International</i> , 2020, 97, 765-777.	5.2	13
14	Revisit ligand-receptor interaction at the human vasopressin V <sub>2</sub> receptor: A kinetic perspective. <i>European Journal of Pharmacology</i> , 2020, 880, 173157.	3.5	8
15	Drug-Target Association Kinetics in Drug Discovery. <i>Trends in Biochemical Sciences</i> , 2019, 44, 861-871.	7.5	42
16	Long residence time adenosine A <sub>1</sub> receptor agonists produce sustained wash-resistant antilipolytic effect in rat adipocytes. <i>Biochemical Pharmacology</i> , 2019, 164, 45-52.	4.4	17
17	The LRP6 functional mutation rs2302685 contributes to individual susceptibility to alcoholic liver injury related to the Wnt/ $\beta$ -catenin-TCF1-CYP2E1 signaling pathway. <i>Archives of Toxicology</i> , 2019, 93, 1679-1695.	4.2	13
18	A two-state model for the kinetics of competitive radioligand binding. <i>British Journal of Pharmacology</i> , 2018, 175, 1719-1730.	5.4	14

#	ARTICLE	IF	CITATIONS
19	Indinavir Alters the Pharmacokinetics of Lamivudine Partially via Inhibition of Multidrug and Toxin Extrusion Protein 1 (MATE1). <i>Pharmaceutical Research</i> , 2018, 35, 14.	3.5	5
20	Functional organic cation transporters mediate osteogenic response to metformin in human umbilical cord mesenchymal stromal cells. <i>Cytotherapy</i> , 2018, 20, 650-659.	0.7	19
21	Metformin induces osteoblastic differentiation of human induced pluripotent stem cell-derived mesenchymal stem cells. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2018, 12, 437-446.	2.7	84
22	Ketamine induces hippocampal apoptosis through a mechanism associated with the caspase-1 dependent pyroptosis. <i>Neuropharmacology</i> , 2018, 128, 63-75.	4.1	40
23	Molecular Basis of Ligand Dissociation from G Protein-Coupled Receptors and Predicting Residence Time. <i>Methods in Molecular Biology</i> , 2018, 1705, 197-206.	0.9	3
24	Novel Calcium Phosphate Cement with Metformin-Loaded Chitosan for Odontogenic Differentiation of Human Dental Pulp Cells. <i>Stem Cells International</i> , 2018, 2018, 1-10.	2.5	29
25	Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). <i>Pharmaceutical Research</i> , 2018, 35, 243.	3.5	24
26	Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. <i>Pharmaceutical Research</i> , 2018, 35, 204.	3.5	22
27	Kinetic Aspects of the Interaction between Ligand and G Protein-Coupled Receptor: The Case of the Adenosine Receptors. <i>Chemical Reviews</i> , 2017, 117, 38-66.	47.7	51
28	Kinetics for Drug Discovery: an industry-driven effort to target drug residence time. <i>Drug Discovery Today</i> , 2017, 22, 896-911.	6.4	165
29	Disturbance of Mammary UDP-Glucuronosyltransferase Represses Estrogen Metabolism and Exacerbates Experimental Breast Cancer. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2152-2162.	3.3	11
30	Metabolic Response to Olanzapine in Healthy Chinese Subjects with rs7093146 Polymorphism in Transcription Factor 7-like 2 Gene ( <i>TCF7L2</i> ): A Prospective Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 601-609.	2.5	2
31	Structure-Activity Relationships of the Sustained Effects of Adenosine A <sub>2A</sub> Receptor Agonists Driven by Slow Dissociation Kinetics. <i>Molecular Pharmacology</i> , 2017, 91, 25-38.	2.3	18
32	Multidrug and toxin extrusion proteins mediate cellular transport of cadmium. <i>Toxicology and Applied Pharmacology</i> , 2017, 314, 55-62.	2.8	19
33	Equilibrium and kinetic selectivity profiling on the human adenosine receptors. <i>Biochemical Pharmacology</i> , 2016, 105, 34-41.	4.4	18
34	5-Substituted Amiloride Derivatives as Allosteric Modulators Binding in the Sodium Ion Pocket of the Adenosine A <sub>2A</sub> Receptor. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4769-4777.	6.4	30
35	The Added Value of Assessing Ligand-Receptor Binding Kinetics in Drug Discovery. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 819-821.	2.8	27
36	Controlling the Dissociation of Ligands from the Adenosine A <sub>2A</sub> Receptor through Modulation of Salt Bridge Strength. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6470-6479.	6.4	151

#	ARTICLE	IF	CITATIONS
37	Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. Drug Metabolism and Disposition, 2016, 44, 489-494.	3.3	18
38	Molecular Basis of Ligand Dissociation from the Adenosine A <sub>2A</sub> Receptor. Molecular Pharmacology, 2016, 89, 485-491.	2.3	72
39	Mass spectrometry-based ligand binding assays on adenosine A1 and A2A receptors. Purinergic Signalling, 2015, 11, 581-594.	2.2	20
40	The Role of Target Binding Kinetics in Drug Discovery. ChemMedChem, 2015, 10, 1793-1796.	3.2	37
41	Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver. Journal of Pharmaceutical Sciences, 2015, 104, 2864-2876.	3.3	19
42	Structure-kinetics relationships of Capadenoson derivatives as adenosine A <sub>1</sub> receptor agonists. European Journal of Medicinal Chemistry, 2015, 101, 681-691.	5.5	28
43	Gating function of isoleucine <sup>116</sup> in $\text{TM}^{\text{E3}}$ (position $\text{III}^{\text{L}}:16/3,40$ ) for the activity state of the $\text{CC}^{\text{E}}$ -chemokine receptor 5 ( $\text{CCR}^{\text{5}}$ ). British Journal of Pharmacology, 2014, 171, 1566-1579.	5.4	10
44	Molecular mechanism of allosteric modulation at $\text{GPCRs}$ : insight from a binding kinetics study at the human $\text{A}_1$ adenosine receptor. British Journal of Pharmacology, 2014, 171, 5295-5312.	5.4	20
45	Drug-Target Residence Time—A Case for G Protein-Coupled Receptors. Medicinal Research Reviews, 2014, 34, 856-892.	10.5	145
46	Binding Kinetics of ZM241385 Derivatives at the Human Adenosine A <sub>2A</sub> Receptor. ChemMedChem, 2014, 9, 752-761.	3.2	45
47	Agonists for the Adenosine A <sub>1</sub> Receptor with Tunable Residence Time. A Case for Nonribose 4-Amino-6-aryl-5-cyano-2-thiopyrimidines. Journal of Medicinal Chemistry, 2014, 57, 3213-3222.	6.4	47
48	Dual-Point Competition Association Assay: A Fast and High-Throughput Kinetic Screening Method for Assessing Ligand-Receptor Binding Kinetics. Journal of Biomolecular Screening, 2013, 18, 309-320.	2.6	65
49	Biased and Constitutive Signaling in the CC-chemokine Receptor CCR5 by Manipulating the Interface between Transmembrane Helices 6 and 7. Journal of Biological Chemistry, 2013, 288, 12511-12521.	3.4	59
50	Functional efficacy of adenosine A <sub>2A</sub> receptor agonists is positively correlated to their receptor residence time. British Journal of Pharmacology, 2012, 166, 1846-1859.	5.4	153
51	GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A <sub>2B</sub> receptor. FASEB Journal, 2011, 25, 632-643.	0.5	44
52	Exploring Chemical Substructures Essential for hERG K <sup>+</sup> Channel Blockade by Synthesis and Biological Evaluation of Dofetilide Analogues. ChemMedChem, 2009, 4, 1722-1732.	3.2	27
53	$\text{PF}^{\text{06409577}}$ inhibits renal cyst progression by concurrently inhibiting the $\text{mTOR}$ pathway and $\text{CFTR}$ channel activity. FEBS Open Bio, 0, .	2.3	3